Summary of the Dutch S3-Guidelines on the treatment of psoriasis 2011

Zweegers, Jeffrey; Jong, E.M.G.J. de; Nijsten, Tamar; Bes, J de; Booij, M te; Borgonjen, R.J.; Cranenburgh, O.D. van; Deutekom, H. van; Everdingen, J.J.E. van; Groot, Marjan de; Hees, C.L.M. van; Hulshuizen, H; Koek, M.B.G.; Korte, W.J.A. de; Korte, J. de; Lecluse, L.L.A.; Pasch, Marcel C.; Poblete‐Gutiérrez, Pamela; Prens, Errol P.; Seyger, M.M.B.; Thio, Hok Bing; Torcque, L.A.; Vries, A.C.Q. de; Kerkhof, P.C.M. van de; Spuls, P.I.

doi:10.5070/d3203021769

Cited by 34 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those treatment differences could, in part, be explained by the specific Dutch guideline on psoriasis, first published in 2003 ( 14 ) and updated at least twice ( 15 , 16 ). In 2003, Dutch dermatologists proposed methotrexate and ciclosporin as the oral treatments for psoriasis, because of a higher efficacy compared with retinoids and fumarates.…”

Section: Discussionmentioning

confidence: 99%

“…It could also be a consequence of updated guidelines, first in 2012 in UK and, secondly, in 2015 at the European level, which proposed methotrexate as the first-choice treatment. In 2011, Dutch guidelines proposed adalimumab or etanercept as first-line biologic agents, because the long-term efficacy and safety profile of ustekinumab were less known compared with those of anti-TNF agents ( 15 ). Despite an update of the Dutch guidelines in 2017, adalimumab and ustekinumab were the first choice of biologic agent, with equal proportions ( 16 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Choice of Systemic Drugs for the Management of Moderate-to-severe Psoriasis: A Cross-country Comparison Based on National Health Insurance Data

Sbidian

Mezzarobba²,

Shourick³

et al. 2021

Acta Derm Venereol

View full text Add to dashboard Cite

Current management of moderate-to-severe psoriasis may be heterogeneous between European countries, probably due to differences in the organization of care. The aim of this study was to compare the utilization of systemic treatments for psoriasis between 2 countries. All adults with psoriasis who were registered in the French (SNDS) and the Dutch (VEKTIS) national health insurance databases between 2012 and 2016 were eligible for inclusion. In France, 105,035 (15%) of 684,156 patients and, in the Netherlands, 37,405 (28.6%) of 130,822 patients received at least a systemic agent. In France, the proportion of patients treated with systemic agents was constant, while the type of drugs dispensed shifted from non-biological to biological agents. In the Netherlands, the first systemic treatment was methotrexate and, in France, acitretin. In France, the choice of the first biologic was much more variable than it was in the Netherlands, where a large proportion of patients were dispensed ustekinumab. This study highlights discrepancies between France and the Netherlands concerning the choice of first non-biologic agent and first biologic agent for patients with psoriasis. These discrepancies may be due to differences in the healthcare systems between the 2 countries.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Choice of Systemic Drugs for the Management of Moderate-to-severe Psoriasis: A Cross-country Comparison Based on National Health Insurance Data

Sbidian

Mezzarobba²,

Shourick³

et al. 2021

Acta Derm Venereol

View full text Add to dashboard Cite

show abstract

“…The Authors concluded that efficacy of Cys-A in childhood psoriasis is "ambiguous" since one case series of 4 young children affected with atypical forms of psoriasis (neonatal, acral, or immunodeficiency-associated) did not show any response [20]. Dutch guidelines duplicated this opinion [24]. Safety issues were sparsely described.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: A multicentric retrospective analysis

Lernia

Stingeni

Boccaletti

et al. 2015

Journal of Dermatological Treatment

View full text Add to dashboard Cite

show abstract

Treatment of Ocular Pyogenic Granuloma With Topical Timolol

et al. 2017

View full text Add to dashboard Cite

yogenic granuloma (PG), also known as lobular capillary hemangioma, is a common acquired vascular lesion that occurs on skin and mucosal surfaces, particularly in the pediatric population. Timolol is a nonselective β-blocker that has been an effective nonsurgical alternative in treating pyogenic granulomas in a handful of case reports. [1][2][3][4][5][6] Most of these reports show the efficacy of timolol in nonocular PGs, with 1 case report 1 showing incidental resolution of an ocular surface PG 6 months after initiation of topical timololdorzolamide for glaucoma. To our knowledge, there are no reports examining the response of ocular surface PGs to topical β-blockers. Herein, we report a case series of ocular surface PGs of varying etiologies showing complete resolution with topical timolol treatment. MethodsThis study adhered to the tenets of the Declaration of Helsinki. The Boston Children's Hospital Institutional Review Board approved the retrospective review of patient records, and informed consent was waived, given the retrospective nature of this study and the fact that all patient identifiers were omitted from analysis and from publication. We identified and included all patients with PG who were treated with topical timolol, 0.5%, between 2014 and 2016 through faculty survey (A.S.S. and R.A.P.) and billing records. We retrospectively reviewed patient medical records to abstract age, etiology, morphology, size, photography, treatment modality, outcome, and follow-up.

show abstract

Summary of the Dutch S3-Guidelines on the treatment of psoriasis 2011

Cited by 34 publications

References 25 publications

Choice of Systemic Drugs for the Management of Moderate-to-severe Psoriasis: A Cross-country Comparison Based on National Health Insurance Data

Choice of Systemic Drugs for the Management of Moderate-to-severe Psoriasis: A Cross-country Comparison Based on National Health Insurance Data

Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: A multicentric retrospective analysis

Treatment of Ocular Pyogenic Granuloma With Topical Timolol

Contact Info

Product

Resources

About